The emerging role of targeted therapy for hematologic malignancies:: Update on bortezomib and tipifarnib
The emerging role of targeted therapy for hematologic malignancies:: Update on bortezomib and tipifarnib
复制标题
DOI：
10.1634/theoncologist.12-3-281
复制
发表时间：
2007-01-01
期刊：
影响因子：
5.8
通讯作者：
Miguel, Jesus San
中科院分区：
文献类型：
--
作者：
Armand, Jean-Pierre;Burnett, Alan K.;Miguel, Jesus San
随着血液恶性肿瘤治疗的发展，针对特定细胞过程的新方案和新药物使许多患者的预后更加乐观。硼替佐米和替法尼是两种新的血液恶性肿瘤靶向治疗药物。硼替佐米是一种蛋白酶体抑制剂，在多发性骨髓瘤复发患者和作为初始治疗（包括自体干细胞移植前）显示出令人印象深刻的疗效。它已被研究作为单一疗法和联合标准治疗，如地塞米松，并与较新的药物，如免疫调节剂沙利度胺和来那度胺；反应是令人鼓舞的，即使在以前接受单一药物治疗后复发的患者中也是如此。硼替佐米通常耐受性良好，包括与新型和传统药物联合使用。替法尼是法尼基转移酶的特异性抑制剂。高风险急性白血病和骨髓增生异常综合征患者的临床试验表明，替法尼具有良好的疗效。对这些新的靶向治疗方法的持续研究将进一步确定它们作为血液病癌症患者的治疗选择。
As therapy for hematologic malignancy evolves, new regimens and novel agents that target specific cellular processes allow a more optimistic prognosis for many patients. Bortezomib and tipifarnib are two new, targeted treatments for hematologic malignancies. Bortezomib, a proteasome inhibitor, has shown impressive efficacy in patients with relapsed multiple myeloma and as initial treatment, including before autologous stem cell transplantation. It has been studied as monotherapy and in combination with standard treatments such as dexamethasone, and with newer agents such as the immunomodulators thalidomide and lenalidomide; response is encouraging, even in patients who have relapsed after previously receiving components of a regimen as single agents. Bortezomib is generally well tolerated, including in combination with novel and conventional agents. Tipifarnib is a specific inhibitor of farnesyltransferase. Clinical trials in patients with high-risk acute leukemias and myelodysplastic syndromes have demonstrated good efficacy with tipifarnib. Continued investigation with these new, targeted treatments will further define their use as treatment options in patients with hematologic cancer.